Oncotarget

Research Papers:

STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer

Sambit K. Mohanty, Kader Yagiz, Dinesh Pradhan, Daniel J. Luthringer, Mahul B. Amin, Serhan Alkan _ and Bekir Cinar

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:85997-86010. https://doi.org/10.18632/oncotarget.20844

Metrics: PDF 1802 views  |   HTML 2701 views  |   ?  


Abstract

Sambit K. Mohanty1, Kader Yagiz2, Dinesh Pradhan3, Daniel J. Luthringer1, Mahul B. Amin4, Serhan Alkan1 and Bekir Cinar5,6

1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

2Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

3University of Pittsburgh Medical Center, Pittsburgh, PA 15238, USA

4Department of Pathology and Laboratory Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA

5Department of Biological Sciences, The Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA

6Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA

Correspondence to:

Serhan Alkan, email: serhan.alkan@cshs.org

Bekir Cinar, email: bcinar@cau.edu

Keywords: STAT3, STAT5A, pimozide, castration-resistance, prostate cancer

Received: April 26, 2017    Accepted: August 03, 2017    Published: September 12, 2017

ABSTRACT

Mechanisms of castration-resistant prostate cancer (CRPC) are not well understood, thus hindering rational-based drug design. Activation of STAT3/5A, key components of the JAK/STAT pathway, is implicated in aggressive PC, yet their clinical relevance in CRPC remains elusive. Here, we evaluated the possible role of STAT3/5A in CRPC using immunological, quantitative mRNA expression profiling, and pharmacological methods. We observed a strong nuclear immunoreactivity for STAT3 and STAT5A in 93% (n=14/15) and 80% (n=12/15) of CRPC cases, respectively, compared with benign prostatic hyperplasia (BPH). We demonstrated that PC cells express varying levels of STAT3 and STAT5A transcripts. In addition, we demonstrate that pimozide, a psychotropic drug and an indirect inhibitor of STAT5, attenuated PC cells growth, and induced apoptosis in a dose-dependent manner. Furthermore, our analysis of the PC public data revealed that the STAT3/5A genes were frequently amplified in metastatic CRPC. These findings suggest that STAT3/5A potentially serves as a predictive biomarker to evaluate the therapeutic efficacy of a cancer drug targeting the JAK/STAT pathway. Since the JAK/STAT and AR pathways are suggested to be functionally synergistic, inhibition of the JAK/STAT signaling alone or together with AR may lead to a novel treatment modality for patients with advanced PC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20844